Vanessa Preumont

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

CGM Metrics and the Risk of Pregnancy Complications in Type 1 Diabetes: A Secondary Exploratory Analysis of the CRISTAL Trial.

CGM Metrics and the Risk of Pregnancy Complications in Type 1 Diabetes: A Secondary Exploratory Analysis of the CRISTAL Trial.

Journal: Diabetes technology & therapeutics

Published: August 12, 2026

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: December 30, 2025

Who Benefits Most from Advanced Hybrid Closed Loop Therapy in Pregnancy Across Different Subgroups: A Secondary Analysis of the Randomized Controlled CRISTAL Trial.

Who Benefits Most from Advanced Hybrid Closed Loop Therapy in Pregnancy Across Different Subgroups: A Secondary Analysis of the Randomized Controlled CRISTAL Trial.

Journal: Diabetes technology & therapeutics

Published: September 23, 2025

Cardiometabolic insights in cystic fibrosis and highly effective modulator therapies: a narrative review.

Cardiometabolic insights in cystic fibrosis and highly effective modulator therapies: a narrative review.

Journal: Endocrine connections

Published: March 10, 2025

One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.

One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.

Journal: Diabetologia

Published: December 02, 2024

Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium.

Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium.

Journal: PharmacoEconomics - open

Published: November 27, 2024

Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial.

Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial.

Journal: EClinicalMedicine

Published: September 20, 2024

Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial.

Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial.

Journal: Diabetes care

Published: June 25, 2024

Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.

Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.

Journal: The lancet. Diabetes & endocrinology

Published: February 23, 2024

Novel time-saving OGTT sparing HbA1c-HOMA2 based algorithm for the diagnosis of cystic fibrosis-related diabetes.

Novel time-saving OGTT sparing HbA1c-HOMA2 based algorithm for the diagnosis of cystic fibrosis-related diabetes.

Journal: Diabetes research and clinical practice

Published: November 06, 2023

Advances in cystic fibrosis-related diabetes: Current status and future directions.

Advances in cystic fibrosis-related diabetes: Current status and future directions.

Journal: Diabetes & metabolic syndrome

Published: May 31, 2023

Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.

Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.

Journal: Journal of clinical & translational endocrinology

Published: March 29, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026